DOI 10.1016/j.jacl.2026.05.001
Comparative efficacy and safety of olezarsen vs plozasiran for familial chylomicronemia syndrome: A matching-adjusted indirect comparison.
Аннотация
BACKGROUND
Familial chylomicronemia syndrome (FCS) is a rare genetic form of primary hypertriglyceridemia with an increased risk of acute pancreatitis (AP). Apolipoprotein C-III (apoC-III) inhibitors, olezarsen and plozasiran, provide therapeutic approaches to reduce triglycerides in patients with FCS.
OBJECTIVE
To compare the efficacy and safety of olezarsen (Balance) with plozasiran (PALISADE) in FCS.
METHODS
An anchored matching-adjusted indirect comparison was conducted. Outcome analyses included only the approved dosages of study therapies, while the AP analysis also pooled high- and low-dose regimens.
RESULTS
Analyses showed no statistically significant differences in 52-week efficacy or safety. Mean differences (olezarsen vs plozasiran) in triglycerides and apoC-III reduction were -15.5% (95% CI: -76.2, 45.2) and -8.4% (95% CI: -69.7, 53.0). Relative risks of AP, treatment-emergent, and serious adverse events were 0.70 (95% CI: 0.07, 6.66), 0.81 (95% CI: 0.58, 1.13), and 0.50 (95% CI: 0.10, 2.58).
CONCLUSION
Overall, there was no evidence of differences in efficacy or safety between olezarsen and plozasiran in the treatment of patients with FCS.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.